

29 January 2024

Analysing the usage of biologic and biosimilar products within Rheumatology

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV 51	SC 222
• Adalimumab [Humira]	411	
• Adalimumab Biosimilars	Imraldi 572	Amgevita 224
• Apremilast [Otezla]	28	
• Baricitinib [Olumiant]	42	
• Bimekizumab [Bimzelx]	<5	
• Certolizumab [Cimzia]	141	
• Etanercept [Enbrel]	118	
• Etanercept Biosimilars	346	
• Filgotinib [Jyseleca]	<5	
• Golimumab [Simponi]	101	
• Guselkumab [Tremfya]	5	
• Infliximab [Remicade]	55	
• Infliximab Biosimilars	IV 42	SC <5
• Ixekizumab [Taltz]	106	
• Risankizumab [Skyrizi]	<5	
• Rituximab [MabThera]	90	
• Rituximab Biosimilars	194	
• Sarilumab [Kevzara]	<5	
• Secukinumab [Cosentyx]	240	
• Tocilizumab [Ro Actemra]	IV 47	SC 151
• Tocilizumab Biosimilars	<5	
• Tofacitinib [Xeljanz]	25	
• Upadacitinib [Rinvoq]	83	
• Ustekinumab [Stelara]	13	

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

• Adalimumab [Humira]	<5	
• Adalimumab Biosimilars	Imraldi <5	Amgevita <5
• Certolizumab [Cimzia]	<5	

29 January 2024

- Etanercept [Enbrel] <5
- Etanercept Biosimilars <5
- Golimumab [Simponi] <5
- Infliximab [Remicade] <5
- Infliximab Biosimilars <5
- Ixekizumab [Taltz] <5
- Secukinumab [Cosentyx] <5
- Tofacitinib [Xeljanz] <5
- Upadacitinib [Rinvoq] <5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.